Drug screening is used to detect illegal and some prescribed drugs in the blood, urine, and other biological samples. It is also used to determine drug use and is an integral part of ongoing evaluation and treatment. Rise in overuse of prescribed drugs, increase in use of narcotics and illicit drugs are some of the major driver for the market. For instance, as per Our World in Data, Illicit drug use is directly and indirectly responsible for over 750,000 deaths per year. Illicit drug use is responsible for 585,000 premature deaths by increasing the risk of disease and injury. Moreover, as per CDC in 2018, over 166,000 die from drug overdoses each year. In 2018, there were 67,367 drug overdose deaths in the United States, a 4.1% decline from 2017 (70,237 deaths). The age-adjusted rate of drug overdose deaths in 2018 (20.7 per 100,000) was 4.6% lower than in 2017 (21.7). For 14 states and the District of Columbia, the drug overdose death rate was lower in 2018 than in 2017. The rate of drug overdose deaths involving synthetic opioids other than methadone (drugs such as fentanyl, fentanyl analogs, and tramadol) increased by 10%, from 9.0 in 2017 to 9.9 in 2018. To curb the menace of drug and alcohol abuse, authorities in various countries are focusing on implementing comprehensive drug and alcohol testing measures. This has boosted the demand for drug and alcohol testing is expected to increase in the coming years.
Based on product and services, the global Drug Screening market is segmented into drug screening products and drug screening services. Currently, drug screening products dominated the market and is expected to maintain its dominance during the forecast period owing to the increased applications of rapid testing devices such as urine testing devices and oral fluid testing devices
Based on sample, the market is divided into urine samples, oral fluid samples, breath samples, hair samples, and other samples. Urine samples dominated the market in 2020 owing to the to the benefits it offers such as high accuracy in the detection of multiple drugs, cost-effectiveness, and instant results
Based on end-users, the market is segmented into workplaces, drug testing laboratories, criminal justice systems & law enforcement agencies, hospitals, drug treatment centers, individual users, pain management centers, and schools & colleges. Currently workplace testing dominates the market and is expected to maintain its dominance during the analyzed period owing to the rowing safety concerns in the workplace and the increasing number of organizations that have made regular drug screening mandatory
For a better understanding of the market adoption, report provide detailed analysis for major region and countries including North America (US, Canada, Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for Drug Screening on account of rising consumption of illicit drugs, availability of government funding to curb drug abuse, and the presence of laws supporting drug screening. However, Asia is expected to register the highest CAGR during the forecast period owing to the growing burden of accidents due to unsafe levels of alcohol consumption
Some of the major players operating in the market includes Siemens, Thermo Fisher, LabCorp, Alere, Omega Laboratories, Roche, OraSure, Biomedical Diagnostics, Quest Diagnostics, Laboratory Corporation of America Holdings; etc.